Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQB2102 in HER2-positive advanced or metastatic biliary tract cancer
CTR20241862Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in biliary cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2024; status: active.
02
Drugs
TQB2102
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20241862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241862.